Cost–Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand
mediaposted on 03.06.2021, 13:16 by Adis journals on behalf of, Chaicharn Deerochanawong, Kriengsak Vareesangthip, Dilok Piyayotai, Dittaya Thongsuk, Nuch Pojchaijongdee, Unchalee Permsuwan
Article full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.